Technology: Substance P-opioid chimeric peptides for pain and subcutaneous biodegradable controlled-release localized delivery system
Disease focus: Neurology
Clinical status: Preclinical
Founded: 2004 by Daniel Carr and Andrzej Lipkowski
University collaborators: New England Medical College at Tufts University;...
Opiates remain the primary treatment for moderate to severe pain, although the tendency to develop tolerance to the drugs and then dependence is a shortcoming for chronic use. Accugesics Inc. is developing chimeric peptides that...